Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's D&A?
- Kymera Therapeutics (KYMR) reported D&A of $2.03M in Q2 2026.
- How has Kymera Therapeutics's D&A changed year-over-year?
- Kymera Therapeutics's D&A decreased by 2.6% year-over-year, from $2.08M to $2.03M.
- What is the long-term trend for Kymera Therapeutics's D&A?
- Over 4 years (2021 to 2025), Kymera Therapeutics's D&A has grown at a 36.5% compound annual growth rate (CAGR), from $2.4M to $8.31M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Kymera Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude